Pharmacogenetics: A new diagnostic tool in the management of antidepressive drug therapy

Clinica Chimica Acta

Volumn 308, Issue 1-2, 2001, Pages 33-41

  Steimer, Werner ^a   Müller, Burkhardt ^a   Leucht, Stefan ^a   Kissling, Werner ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Cytochrome P450 2D6 (CYP2D6); Pharmacogenetics; Serotonin transporter polymorphism; SSRI; Therapeutic drug monitoring; Tricyclic antidepressants (TCA)

Indexed keywords

AMITRIPTYLINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; DEBRISOQUINE; DESIPRAMINE; DEXTROMETHORPHAN; DRUG METABOLIZING ENZYME; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MEPHENYTOIN; MIANSERIN; MIDAZOLAM; MOCLOBEMIDE; NEFAZODONE; NORCITALOPRAM; NORFLUOXETINE; NORTRIPTYLINE; PAROXETINE; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; SPARTEINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

CAUSE OF DEATH; COMPARATIVE STUDY; DEPRESSION; DIAGNOSTIC TEST; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; REVIEW; UNITED STATES;

ANTIDEPRESSIVE AGENTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; CARRIER PROTEINS; CYTOCHROME P-450 CYP2D6; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MEMBRANE GLYCOPROTEINS; MEMBRANE TRANSPORT PROTEINS; NERVE TISSUE PROTEINS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS;

EID: 0034966799     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-8981(01)00423-5     Document Type: Review

References (52)

1. Depressive illness
2. Defining the boundaries of atypical depression
3. Therapeutic drug monitoring. Principles and practice
4. Brain concentrations of tricyclic antidepressants: Single dose kinetics and relationship to plasma concentrations in chronically dosed rats
5. Therapeutic drug monitoring of antidepressants: Cost implications and relevance to clinical practice
6. Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution
7. Debrisoquine/sparteine hydroxylation genotype and phenotype: Analysis of common mutations and alleles of CYP2D6 in a European population
8. Analysis of the CYP2D6 gene in relation to debrisoquin and desipramine hydroxylation in a Swedish population
9. CYP2D6 genotype determination in the Danish population
10. Polymorphic debrisoquin hydroxylation in 757 Swedish subjects
11. Drug-metabolizing enzymes and therapeutic drug monitoring in psychiatry
12. Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine
13. Molecular basis for rational megaprescribing in ultrarapid hydroxylators of debrisoquine
14. Ultrarapid hydroxylation of debrisoquine in a Swedish population. Analysis of the molecular genetic basis
15. Prevalence of CYP2D6 gene duplication and its repercussion on the oxidative phenotype in a white population
16. Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone
17. Pilot study of the cytochrome P450-2D6 genotype in a psychiatric state hospital
18. Pharmacogenetics: Genotyping of cytochromes P450 2D6 and 2C19 in psychiatric patients treated with tricyclic antidepressants (TCA) or neuroleptics
19. Pharmacogenetics of antidepressants: Clinical aspects
20. Pharmacogenetics of cytochrome P450
21. Advances in understanding drug metabolism and its contribution to variability in patient response
22. Pharmacogenetics: A laboratory tool for optimizing therapeutic efficiency
23. Clinical implications of antidepressant pharmacokinetics and pharmacogenetics
24. Cytochrome P450 2D6 variants in a Caucasian population: Allele frequencies and phenotypic consequences
25. CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles
26. Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population
27. Pharmacogenetic methods as a complement to therapeutic monitoring of antidepressants and neuroleptics
28. The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry
29. Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: A prospective study
30. Drug-drug interactions
31. Effect of adjunctive paroxetine on serum levels and side-effects of tricyclic antidepressants in depressive inpatients
32. Recent pharmacologic advances in antidepressant therapy for the elderly
33. Is therapeutic drug monitoring a case for optimizing clinical outcome and avoiding interactions of the selective serotonin reuptake inhibitors?
34. To monitor or not to monitor: II. The glass is more than half full
35. Clinical pharmacokinetics of selective serotonin reuptake inhibitors
36. Serotonin transporter gene polymorphism and antidepressant response
37. Antidepressant- and cocaine-sensitive human serotonin transporter: Molecular cloning, expression, and chromosomal localization
38. Organization of the human serotonin transporter gene
39. Population studies of polymorphisms of the serotonin transporter protein gene
40. Allelic variation of human serotonin transporter gene expression
41. Serotonin transporter protein (SLC6A4) allele and haplotype frequencies and linkage disequilibria in African- and European-American and Japanese populations and in alcohol-dependent subjects
42. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region
43. Analysis and meta-analysis of two serotonin transporter gene polymorphisms in bipolar and unipolar affective disorders
44. A variable-number-tandem-repeat of the serotonin transporter gene and anxiety disorders
45. Obsessive compulsive disorder, response to serotonin reuptake inhibitors and the serotonin transporter gene
46. Evidence for linkage disequilibrium between serotonin transporter protein gene (SLC6A4) and obsessive compulsive disorder
47. Association of the serotonin transporter promoter regulatory region polymorphism and obsessive-compulsive disorder
48. Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine
49. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene
50. Influence of a functional polymorphism within the promoter of the serotonin transporter gene on the effects of total sleep deprivation in bipolar depression
51. Pharmacogenetics
52. Incidence of adverse drug reactions in hospitalized patients: A meta-analysis of prospective studies